CDK4 and neoplasm: In the present study, we aimed to evaluate the synergistic effects of combining RT with CDK4/6 inhibitors and anti-PD-L1 antibodies on tumor suppression in vivo using 4T1 and EMT6 immunocompetent mouse models.